search
Back to results

A Study to Evaluate the Safety, Pharmacokinetics and Biodistribution of an Imaging Agent, 18F-OP-801 (18F Hydroxyl Dendrimer) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Healthy Volunteers (HV)

Primary Purpose

Amyotrophic Lateral Sclerosis (ALS)

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
18F-OP-801
Sponsored by
Ashvattha Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Amyotrophic Lateral Sclerosis (ALS)

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Adult (Age 18-80, inclusive) at the Screening Visit.
  2. Has the ability to understand and sign the written ICF and local medical privacy authorization forms, which must be obtained prior to the conduct of any study related procedures.
  3. Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit) or postmenopausal, defined as spontaneous amenorrhea for at least 2 years, with follicle-stimulating hormone (FSH) in the postmenopausal range at screening, based on the local laboratory's defined ranges.
  4. Female subjects of childbearing potential (i.e., ovulating, premenopausal, and not surgically sterile) and all male subjects must use a medically accepted contraceptive regimen (including hormonal contraceptives) during their participation in the study and for 90 days (males) or 6 months (females) after Day 1. Medically accepted contraceptive methods are defined as those with 90% or greater efficacy.
  5. Acceptable methods of contraception for male subjects enrolled in the study include the following:

    1. Condoms or surgical sterilization of subject at least 26 weeks before the Screening Visit (i.e., vasectomy).

      Acceptable methods of contraception for female subjects enrolled in the study include the following:

    2. Surgical sterilization at least 26 weeks before the Screening Visit (includes hysterectomy or bilateral tubal ligation, bilateral oophorectomy, or salpingectomy);
    3. Intrauterine device or diaphragm with spermicide for at least 12 weeks before the Screening Visit; or
    4. Hormonal contraception (oral, implant, injection, ring, or patch) for at least 12 weeks before the Screening Visit.
  6. If male, subjects must agree to abstain from sperm donation through 90 days after the Day 1 Visit.
  7. Female subjects may not be pregnant, lactating, or breastfeeding.
  8. Female subjects of childbearing potential must have negative result for pregnancy test at Screening and Check-in.
  9. Subjects must have an estimated glomerular filtration rate (eGFR) of >45 mL/min/1.73m2 at Screening.
  10. C-reactive protein level ≤10 mg/dL.
  11. Subjects must be willing and able to abide by all study requirements and restrictions.

    Inclusion Specific to ALS Subjects:

  12. Serum NfL concentration at Screening Visit above the 95th percentile of the reference range for healthy subjects of the same age (using reference data).
  13. Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by the modified El Escorial criteria.
  14. ALS cognitive behavioral screen score >10 on the cognitive scale and/or >32 on the behavioral scale.
  15. Forced vital capacity (FVC) of ≥50%; or if in the opinion of the investigator can lay flat for up to 90 minutes. If FVC has been performed within the past 6 months, this data may be used at the discretion of the investigator.
  16. Medications for ALS subjects should be stable for 30 days prior to the Screening Visit and remain unchanged during the subject's participation in the study.

Exclusion Criteria:

  1. Body weight > 120 kg.
  2. Evidence of clinically significant or past medical history of hematologic, renal, endocrine, pulmonary, cardiac, gastrointestinal, hepatic, psychiatric, neurologic, immunologic, allergic disease (including multiple or clinically significant drug allergies), or any other condition that, in the opinion of the Investigator, might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the subject at an unacceptable risk as a participant in this study.
  3. History of recurrent kidney or liver malignancy.
  4. Pacemaker or defibrillator or any non-removable metallic foreign objects in the body not compatible with MRI.
  5. Inability to lie in a PET/CT or PET/MRI scanner for up to 90 minutes.
  6. Laboratory results (serum chemistry, hematology, coagulation, and urinalysis) outside the normal range at screening and check-in and considered clinically significant in the opinion of the Investigator. Any elevation of aspartate transaminase (AST) and alanine transaminase (ALT) more than 3 times the above upper limit of normal at screening and/or check-in is exclusionary. One retest of an exclusionary laboratory result is allowed at the discretion of the Investigator, with approval from the Medical Monitor.
  7. Resolved acute illness considered clinically significant by the Investigator within 10 days prior to screening.
  8. History of alcoholism or drug abuse within 2 years prior to screening. No cannabinoid drug use for at least 10 days prior to Day 1.
  9. Positive urine drug test, marijuana test, or cotinine test at Screening or Check-In.
  10. Any immunizations within the 28 days prior to screening, with the exception of a COVID-19 vaccine or booster.
  11. Received any other investigational medicinal product within 30 days or 5 half-lives of the investigational medicinal product (whichever is longer) prior to Day 1.
  12. Treatment with immunosuppressive agents (e.g., prednisone, solumedrol) within 30 days of Day 1. Treatment with anti-inflammatory agents including any medications in the following classes of nonsteroidal anti-inflammatory drugs (NSAIDS): carboxylic acids, enolic acids, cyclooxygenase (COX) II inhibitors within 14 days of Day 1.
  13. Lost or donated >450 mL of whole blood or blood products within 30 days prior to screening.
  14. MRI exclusion criteria include: findings that may interfere with interpretation of the PET imaging, including but not limited to significant cortical/subcortical cerebrovascular disease, infectious disease, space-occupying lesions, hydrocephalus or other abnormalities associated with CNS disease.
  15. CT exclusion criteria include any medical device or metallic implant that may interfere with image acquisition or affect image reconstruction (e.g. CT attenuation correction).
  16. Investigator has reason to believe that the subject may be unable to fulfill the protocol visit schedule or requirements.
  17. Has any finding that, in the view of the Investigator and Medical Monitor, would compromise the subject's safety requirements.
  18. Is employed by the Sponsor, the CRO, or the study site (permanent, temporary contract worker, or designee responsible for the direct conduct of the study), or is a family member (spouse, parent, sibling, or child) of the Sponsor, CRO, or study site employee.

    Exclusion Criteria Specific to HV Subjects:

  19. Clinically relevant finding on physical examination at screening.
  20. Family history of ALS or frontotemporal dementia.
  21. History of any central nervous system disorder or brain trauma (concussions, etc.).

    1. Medical monitor must be consulted for potential inclusion of subject with history of CNS involvement.

Sites / Locations

  • Stanford UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Healthy Volunteers participants

Amyotrophic Lateral Sclerosis participants

Arm Description

Intravenous Administration of 18F-OP-801 (18F Hydroxyl Dendrimer)

Intravenous Administration of 18F-OP-801 (18F Hydroxyl Dendrimer)

Outcomes

Primary Outcome Measures

The number of participants with treatment emergent adverse events (Safety and Tolerability)
Safety of single dose of 18F-OP-801 as measured by treatment-related adverse events as assessed by CTCAE v5.0

Secondary Outcome Measures

Measurement of biodistribution of 18F-OP-801 for each participant
Measure biodistribution of 18F-OP-801 using whole body PET/MRI or PET/computed tomography (CT) scans
Uptake of 18F-OP-801 in ALS participants
Determination of the correlation between MRI and PET images in the same ALS subjects, quantifying the extent of 18F-OP-801 uptake in the region of neuroinflammation relative to normal brain section in the same ALS subject as measured by whole body PET/MRI or PET/CT scans
Measurement of clearance of 18F-OP-801 for each participant
Measure clearance of 18F-OP-801 using whole body PET/MRI or PET/computed tomography (CT) scans

Full Information

First Posted
May 13, 2022
Last Updated
April 28, 2023
Sponsor
Ashvattha Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT05395624
Brief Title
A Study to Evaluate the Safety, Pharmacokinetics and Biodistribution of an Imaging Agent, 18F-OP-801 (18F Hydroxyl Dendrimer) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Healthy Volunteers (HV)
Official Title
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics and Biodistribution of an Imaging Agent, 18F-OP-801 (18F Hydroxyl Dendrimer), After Intravenous Administration to Patients With Amyotrophic Lateral Sclerosis (ALS) and Healthy Volunteers (HV)
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 2, 2023 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
June 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ashvattha Therapeutics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics and Biodistribution of an Imaging agent, 18F-OP-801 (18F Hydroxyl Dendrimer), After Intravenous Administration to Patients with Amyotrophic Lateral Sclerosis (ALS) and Healthy Volunteers (HV)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Amyotrophic Lateral Sclerosis (ALS)

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
26 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Healthy Volunteers participants
Arm Type
Experimental
Arm Description
Intravenous Administration of 18F-OP-801 (18F Hydroxyl Dendrimer)
Arm Title
Amyotrophic Lateral Sclerosis participants
Arm Type
Experimental
Arm Description
Intravenous Administration of 18F-OP-801 (18F Hydroxyl Dendrimer)
Intervention Type
Drug
Intervention Name(s)
18F-OP-801
Other Intervention Name(s)
18F Hydroxyl Dendrimer
Intervention Description
18F Hydroxyl Dendrimer
Primary Outcome Measure Information:
Title
The number of participants with treatment emergent adverse events (Safety and Tolerability)
Description
Safety of single dose of 18F-OP-801 as measured by treatment-related adverse events as assessed by CTCAE v5.0
Time Frame
Safety and tolerability of 18F-OP-801 as assessed by the frequency, and severity of treatment-emergent adverse events (TEAEs) from Day 1 to Day 15 or Day 18-29
Secondary Outcome Measure Information:
Title
Measurement of biodistribution of 18F-OP-801 for each participant
Description
Measure biodistribution of 18F-OP-801 using whole body PET/MRI or PET/computed tomography (CT) scans
Time Frame
Through study completion at Day 15 or Day 18-29
Title
Uptake of 18F-OP-801 in ALS participants
Description
Determination of the correlation between MRI and PET images in the same ALS subjects, quantifying the extent of 18F-OP-801 uptake in the region of neuroinflammation relative to normal brain section in the same ALS subject as measured by whole body PET/MRI or PET/CT scans
Time Frame
Through study completion at Day 15 or Day 18-29
Title
Measurement of clearance of 18F-OP-801 for each participant
Description
Measure clearance of 18F-OP-801 using whole body PET/MRI or PET/computed tomography (CT) scans
Time Frame
Through study completion at Day 15 or Day 18-29
Other Pre-specified Outcome Measures:
Title
Biomarker levels in blood serum and plasma for each participant
Description
Evaluate blood serum and plasma levels for various biomarkers
Time Frame
Screening and Day 1 pre-dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adult (Age 18-80, inclusive) at the Screening Visit. Has the ability to understand and sign the written ICF and local medical privacy authorization forms, which must be obtained prior to the conduct of any study related procedures. Female subjects of non-childbearing potential must be either surgically sterile (hysterectomy, bilateral tubal ligation, salpingectomy, and/or bilateral oophorectomy at least 26 weeks before the Screening Visit) or postmenopausal, defined as spontaneous amenorrhea for at least 2 years, with follicle-stimulating hormone (FSH) in the postmenopausal range at screening, based on the local laboratory's defined ranges. Female subjects of childbearing potential (i.e., ovulating, premenopausal, and not surgically sterile) and all male subjects must agree to practice abstinence from sexual intercourse or use a medically accepted contraceptive regimen (including hormonal contraceptives) during their participation in the study and for 90 days (males) or 6 months (females) after Day 1. Medically accepted contraceptive methods are defined as those with 90% or greater efficacy. Acceptable methods of contraception for male subjects enrolled in the study include the following: Condoms or surgical sterilization of subject at least 26 weeks before the Screening Visit (i.e., vasectomy). Acceptable methods of contraception for female subjects enrolled in the study include the following: Surgical sterilization at least 26 weeks before the Screening Visit (includes hysterectomy or bilateral tubal ligation, bilateral oophorectomy, or salpingectomy); Intrauterine device or diaphragm with spermicide for at least 12 weeks before the Screening Visit; or Hormonal contraception (oral, implant, injection, ring, or patch) for at least 12 weeks before the Screening Visit. If male, subjects must agree to abstain from sperm donation through 90 days after the Day 1 Visit. Female subjects may not be pregnant, lactating, or breastfeeding. Female subjects of childbearing potential must have negative result for pregnancy test at Screening and Check-in. Subjects must have an estimated glomerular filtration rate (eGFR) of >45 mL/min/1.73m2 at Screening. C-reactive protein level ≤10 mg/dL. Subjects must be willing and able to abide by all study requirements and restrictions. Inclusion Specific to ALS Subjects: Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by the modified El Escorial criteria. Forced vital capacity (FVC) of ≥50%; or if in the opinion of the investigator can lay flat for up to 90 minutes. If FVC has been performed within the past 6 months, this data may be used at the discretion of the investigator. For ALS subjects, medication changes within 30 days prior to the Screening Visit should be discussed with the Medical Monitor. Exclusion Criteria: Body weight > 120 kg. Evidence of clinically significant or past medical history of hematologic, renal, endocrine, pulmonary, cardiac, gastrointestinal, hepatic, psychiatric, neurologic, immunologic, allergic disease (including multiple or clinically significant drug allergies), or any other condition that, in the opinion of the Investigator, might significantly interfere with the absorption, distribution, metabolism, or excretion of study drug, or place the subject at an unacceptable risk as a participant in this study. History of recurrent kidney or liver malignancy. Pacemaker or defibrillator or any non-removable metallic foreign objects in the body not compatible with MRI. Inability to lie in a PET/CT or PET/MRI scanner for up to 90 minutes. Laboratory results (serum chemistry, hematology, coagulation, and urinalysis) outside the normal range at screening and check-in and considered clinically significant in the opinion of the Investigator. Any elevation of aspartate transaminase (AST) and alanine transaminase (ALT) more than 3 times the above upper limit of normal at screening and/or check-in is exclusionary. One retest of an exclusionary laboratory result is allowed at the discretion of the Investigator, with approval from the Medical Monitor. Resolved acute illness considered clinically significant by the Investigator within 10 days prior to screening. History of alcoholism or drug abuse within 2 years prior to screening. No cannabinoid drug use for at least 10 days prior to Day 1. Positive urine drug test, marijuana test, or cotinine test at Screening or Check-In. Any immunizations within the 28 days prior to screening Received any other investigational medicinal product within 30 days or 5 half-lives of the investigational medicinal product (whichever is longer) prior to Day 1. Treatment with immunosuppressive agents (e.g., prednisone, solumedrol) within 30 days of Day 1. Treatment within 14 days of Day 1 with anti-inflammatory agents including any medications in the following classes of nonsteroidal anti-inflammatory drugs (NSAIDS): carboxylic acids, enolic acids, cyclooxygenase (COX) II inhibitors. Lost or donated >450 mL of whole blood or blood products within 30 days prior to screening. MRI exclusion criteria include: findings that may interfere with interpretation of the PET imaging, including but not limited to significant cortical/subcortical cerebrovascular disease, infectious disease, space-occupying lesions, hydrocephalus or other abnormalities associated with CNS disease. CT exclusion criteria include any medical device or metallic implant that may interfere with image acquisition or affect image reconstruction (e.g. CT attenuation correction). Investigator has reason to believe that the subject may be unable to fulfill the protocol visit schedule or requirements. Has any finding that, in the view of the Investigator and Medical Monitor, would compromise the subject's safety requirements. Exclusion Criteria Specific to HV Subjects: Clinically relevant finding on physical examination at screening. Family history of ALS or frontotemporal dementia. History of any central nervous system disorder or brain trauma (concussions, etc.); Medical monitor must be consulted for potential inclusion.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jenni Herber
Phone
650-505-5058
Email
jherber@avttx.com
Facility Information:
Facility Name
Stanford University
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maria Jovin
Phone
650-724-0156
Email
mijovin@stanford.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study to Evaluate the Safety, Pharmacokinetics and Biodistribution of an Imaging Agent, 18F-OP-801 (18F Hydroxyl Dendrimer) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Healthy Volunteers (HV)

We'll reach out to this number within 24 hrs